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Abstract: This study aimed to evaluate the efficacy of pitavastatin pretreatment on contrast-induced
nephropathy (CIN) in patients with chronic kidney disease (CKD) after a coronary procedure.
This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial.
All consecutive 70 patients with CKD (eGFR < 60 mL/min/1.73 m2) were enrolled and randomized
into two groups. Group I consisted of patients who were treated with statins (pitavastatin 4 mg/day)
for seven days before and three days after the procedure (n = 37, 52.9%), and group II consisted of
patients who were treated with a placebo (n = 33, 47.1%). The primary endpoint was the incidence of
CIN, and the secondary endpoints were the change in serum creatinine (∆sCr) level and estimated
glomerular filtration rate (∆eGFR) after the procedure. The mean age of the patients (males, 74%)
was 70.4 ± 9.0 years. After the coronary procedure, the incidence of CIN was lower in group I than in
group II, but the difference was not significant (5.4% vs. 9.1%, p = 0.661). The maximal ∆sCr was
lower and the maximal ∆eGFR was higher in group I than in group II, but the difference was not
significant (−0.11 ± 0.53 mg/dL and −0.04 ± 0.33 mg/dL, p = 0.678; 4.3 ± 11.2 mL/min/1.73 m2 and
−2.9 ± 20.4 mL/min/1.73 m2, p = 0.161, respectively). This study showed the possibility of a clinical
benefit of pretreatment with a high dose of pitavastatin for the prevention of CIN in patients with
CKD after coronary procedure (ClinicalTrials.gov Identifier: NCT01871792).
Keywords: pitavastatin; contrast-induced nephropathy; chronic kidney disease
1. Introduction
Contrast-induced nephropathy (CIN) is a major complication associated with adverse outcomes
after coronary procedure in patients with chronic kidney disease (CKD) [1–3]. The mechanisms of
CIN are not clearly defined. CIN may be related to renal tubular toxicity, vasoconstriction, and high
oxidative stress [4]. Statins have favorable effects on endothelial function, nitric oxide production,
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and oxidative stress, which may be related to the development of CIN [5,6]. Hence, statins have been
proposed for the prevention of CIN, given their antioxidant and anti-inflammatory properties [7,8].
However, their efficacy for the prevention of CIN is controversial [9–13]. The results of statin treatment
might be influenced by the patient population, type or dose of statins, and duration of statin treatment
before and after coronary procedure. This study aimed to evaluate the efficacy of the administration of
short-term high-dose pitavastatin, added to routine intravenous hydration, in reducing the occurrence
of CIN in patients with CKD undergoing a planned coronary procedure.
2. Materials and Methods
This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical
trial performed in patients with CKD undergoing elective coronary angiography and/or intervention
(NCT01871792). From September 2013 to February 2016, 107 patients who had an estimated glomerular
filtration rate (eGFR) of <60 mL/min underwent planned coronary procedures and were considered
eligible for inclusion in our study. Patients undergoing current treatment with a statin, those with
contraindication to statin treatment, those administered contrast media (within 10 days of entry into
the study), those with end-stage renal failure requiring dialysis, and those who refused to provide
informed consent were excluded. Of 107 patients, 26 patients were excluded due to declining to
participate, loss of follow-up and poor general condition. Finally, 81 patients were enrolled in the
study (Figure 1).
Figure 1. Patient flowchart.
Randomization was performed using computerized assignment in a consecutive manner. In total,
44 patients were randomized to receive 4 mg pitavastatin (Livalo, Choongwae Pharma, Seoul, Republic
of Korea) every morning, from 7 days before to 3 days after coronary procedure (total dose of 40 mg of
pitavastatin over 10 days), and 37 patients were randomized to receive a matching placebo for the
same period before and after coronary procedure. Statin therapy was resumed in both groups 3 days
after the procedure, following completion of the study endpoints. Standard hydration therapy was
administered at the discretion of the physician; the therapy included isotonic saline solution (0.9%
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sodium chloride, 1 mL/kg/h), and it was started 12 h before and continued for 24 h after the procedure.
The iso-osmolar, nonionic contrast medium iodixanol (320 mg iodine/mL; Visipaque, GE Healthcare,
Piscataway, NJ, USA) was administered during all procedures. Blood samples were collected to
measure parameters before randomization and at 24 h and 48 h after the procedure. Renal function
was measured using eGFR in all patients. The Institutional Review Board of Gachon University Gil
Medical Center approved this study (GDIRB 2013-21), and all patients provided written informed
consent prior to enrollment.
Serum creatinine (sCr) concentration was assessed at the time of hospital admission and at 24 and
48 h after the coronary procedure. The primary endpoint was the development of CIN, defined as
≥0.5 mg/dL or a ≥25% increase in sCr concentration above baseline within 48 h after exposure to the
contrast medium. The secondary endpoints were the maximal change in sCr and eGFR after exposure
to the contrast medium. Clinical outcomes included the following events occurring within 30 days
of the procedure: (1) all-cause death, and (2) dialysis or hemofiltration due to symptoms or signs of
uremic syndrome or management of refractory hypervolemia, hyperkalemia, or acidosis. All patients
underwent a follow-up evaluation at the clinic or via telephonic contact at 30 days.
Statistical analysis was performed using SPSS 20.0 (SPSS, Inc., Chicago, IL, USA). Categorical
variables were presented as counts and percentages and compared using Chi-square or Fisher’s exact
test. Continuous variables were compared using the Student’s t-test for normally distributed values;
the Mann–Whitney U-test was used for other variables. All p-values were two tailed, and statistical
significance was defined as a p-value < 0.05.
3. Results
3.1. Baseline Characteristics between Patients Pretreated with Pitavastatin and Placebo
The mean age of the patients (74% male) was 70.4 ± 9.0 years. Their mean baseline sCr and eGFR
were 1.59 ± 0.75 mg/dL and 47.5 ± 20.4 mL/min/1.73 m2, respectively. Of these, 15.7% of patients
had severe renal impairment, with eGFR < 30 mL/min/1.73 m2. The baseline clinical, laboratory, and
procedural characteristics did not significantly differ between the groups (Table 1). The proportion
of patients with diabetes mellitus, dyslipidemia, previous percutaneous coronary intervention (PCI),
and history of cerebrovascular accident was higher in group I than in group II, however the difference
was not significant. The values of left ventricular ejection fraction and lipid profile were also similar
between the groups. PCI was performed in 40.5% of patients in group I and 39.4% of patients in
group II. The mean sCr and eGFR values are listed in Table 2. The baseline sCr (1.68 ± 1.03 mg/dL vs.
1.53 ± 0.62 mg/dL, p = 0.575) and eGFR (46.5 ± 15.1 mL/min/1.73 m2 vs. 49.1 ± 23.9 mL/min/1.73 m2,
p = 0.677) levels were similar between the groups (Table 2).
3.2. Preventive Effect of Statins on CIN and Clinical Outcomes during Follow-Up
The primary CIN endpoint occurred in a total of five patients (7.1%): two patients (5.4%) in group I
and three patients (9.1%) in group II (p = 0.661; Figure 2). The changes in sCr and eGFR values after the
coronary procedure are listed in Table 2. The maximal change in sCr was lower and maximal change
in eGFR was higher in group I than in group II, but the difference was not significant (−0.11 ± 0.53
mg/dL and −0.04 ± 0.33 mg/dL, p = 0.678; 4.3 ± 11.2 mL/min/1.73 m2 and −2.9 ± 20.4 mL/min/1.73 m2,
p = 0.161, respectively). No clinical event, including death, dialysis, or hemofiltration due to symptoms
or signs of uremic syndrome or management of refractory hypervolemia, hyperkalemia, or acidosis,
was observed after the procedure and during the 30-day follow-up period.
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(n = 33) p-Value
Age (years) 70.8 ± 8.9 70.0 ± 9.2 0.720
Height (cm) 162.3 ± 10.3 163.1 ± 7.2 0.702
Weight (kg) 66.5 ± 11.2 65.1 ± 9.9 0.575
BMI (kg/m2) 25.2 ± 3.3 24.4 ± 2.7 0.265
Male, n (%) 26 (70.3) 26 (78.8) 0.585
Smoker, n (%) 10 (27.0) 7 (21.2) 0.592
Hypertension, n (%) 28 (75.7) 22 (66.7) 0.438
Diabetes mellitus, n (%) 23 (62.2) 16 (48.5) 0.336
Dyslipidemia, n (%) 11 (29.7) 5 (15.2) 0.167
Previous MI, n (%) 7 (18.9) 5 (15.2) 0.758
Previous PCI, n (%) 15 (40.5) 8 (24.2) 0.204
Previous CVA, n (%) 10 (27.0) 4 (12.1) 0.144
Congestive heart failure, n (%) 7 (23.3) 6 (25.0) 1.000
Myocardial ischemia, n (%) 0.728
Stable angina 23 (62.2) 21 (63.6)
Unstable angina 6 (16.2) 7 (21.2)
NSTEMI 8 (21.6) 5 (15.2)
LVEF, % 58.1 ± 10.1 55.6 ± 9.3 0.342
Medications, n (%)
Aspirin 37 (100) 33 (100) 1.000
Clopidogrel 25 (67.6) 21 (63.6) 0.651
ACEI or ARB 23 (62.2) 18 (54.5) 0.628
Beta-blocker 17 (45.9) 16 (48.5) 0.687
CCB 12 (32.4) 5 (15.2) 0.105
Laboratory determinations, mg/dL
Total cholesterol 162.9 ± 36.6 178.2 ± 35.1 0.117
Triglyceride 105.1 ± 97.4 108.7 ± 134.5 0.898
HDL-C 30.3 ± 23.2 35.5 ± 28.4 0.417
LDL-C 85.6 ± 35.3 93.2 ± 35.9 0.485
HgA1C 6.6 ± 1.0 6.5 ± 1.3 0.826
Fasting glucose 115.6 ± 65.5 104.9 ± 77.0 0.536
Procedure, n (%) 1.000
CAG 22 (59.5) 20 (60.6)
PCI 15 (40.5) 13 (39.4)
BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary intervention; CVA: cerebrovascular
accident; NSTEMI: non-ST elevation myocardial infarction; LVEF: left ventricular ejection fraction;
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CCB: calcium channel blocker;
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HgA1C: Hemoglobin A1C;
CAG: coronary angiography.




(n = 33) p-Value
Baseline
sCr, mg/dL 1.68 ± 1.03 1.53 ± 0.62 0.575
eGFR, mL/min/1.73 m2 46.5 ± 15.1 49.1 ± 23.9 0.677
Follow-up
24 h sCr, mg/dL 1.62 ± 0.88 1.40 ± 0.67 0.414
24 h ∆sCr, mg/dL −0.13 ± 0.39 −0.10 ± 0.24 0.784
48 h sCr, mg/dL 1.49 ± 0.66 1.38 ± 0.53 0.573
48 h ∆sCr, mg/dL −0.08 ± 0.44 −0.06 ± 0.23 0.870
Maximal ∆sCr, mg/dL −0.11±0.53 −0.04±0.33 0.678
24 h eGFR, mg/dL,
mL/min/1.73 m2 53.3 ± 17.9 48.5 ± 17.3 0.433
24 h ∆eGFR,
mL/min/1.73 m2 5.7 ± 12.1 −1.9 ± 22.3 0.205
48 h eGFR, mg/dL,
mL/min/1.73 m2 52.0 ± 16.6 50.1 ± 17.8 0.753
48 h ∆eGFR,
mL/min/1.73 m2 4.3 ± 10.1 −1.5 ± 24.9 0.371
Maximal ∆eGFR-all,
mL/min/1.73 m2 4.3 ± 11.2 −2.9 ± 20.4 0.161
Maximal ∆eGFR,
mL/min/1.73 m2 1.9 ± 11.0 −8.2 ± 28.5 0.212
sCr: serum creatinine; eGFR: estimated glomerular filtration rate; ∆sCr: change in serum creatinine level; ∆eGFR:
change in estimated glomerular filtration rate; CIN: contrast-induced nephropathy.
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Figure 2. Primary endpoint: CIN occurrence.
4. Discussion
To the best of our knowledge, this is the first prospective, randomized, double-blinded,
placebo-controlled clinical trial to evaluate the efficacy of pitavastatin therapy for the prevention of CIN
in patients with mild-to-moderate CKD. In this trial, we observed that periprocedural administration
of pitavastatin 4 mg daily before and after a coronary procedure (10 days) might reduce the incidence
of CIN in patients with CKD. The maximal change in sCr was lower and maximal change in eGFR was
higher in patients pretreated with pitavastatin after coronary procedure. These findings suggest that
pretreatment with pitavastatin prevents worsening of renal function in patients with CKD after use
of contrast medium. Because CIN is a severe complication in patients with already impaired kidney
function, such as in patients included in our study, these results have clinical significance [1–3].
Although the mechanisms of CIN are not clearly defined, endothelin-mediated intensive
vasoconstriction, nitric oxide-mediated inhibition of vasodilation, and oxidative stress caused by
reactive oxygen species are responsible for the development of CIN [4]. Statins are principal therapeutic
agents in lowering blood cholesterol. The beneficial and protective effects on endothelial cells may
lead to increased synthesis of nitric oxide, regression of atherosclerotic plaque, and inhibition of
inflammatory process in ischemic heart disease and renal dysfunction [14–16]. Much evidence has
suggested that statins may play a crucial role in the prevention of CIN through their pleiotropic
effect. [7,8] (Figure 3).
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Figure 3. Potential mechanisms of beneficial effects of statins on the CIN. NO: nitric oxide.
However, previous studies regarding the impact of pretreatment with statins on the incidence
of CIN have showed conflicting results [9–13]. The prevention of CIN using short-term high-dose
simvastatin in patients with CKD undergoing coronary angiography study was the first randomized,
prospective trial focused on the role of short-term statin therapy for the prevention of CIN [10].
However, the results of this study showed that short-term pretreatment (48 h) with high-dose
simvastatin (40 mg twice a day) did not prevent the deterioration of renal function in patients with CKD
who received intravenous hydration. In another study, short-term administration (48 h before and 48 h
after contrast exposure) of high doses of atorvastatin (80 mg/day), in addition to standard intravenous
hydration and oral N-acetylcysteine, also did not reduce the occurrence of CIN in patients with
CKD [12]. On the contrary, Han et al. reported that rosuvastatin (10 mg/day, for 5 days: 2 days before
and 3 days after the procedure) significantly reduced the risk of CIN in patients with type 2 diabetes
mellitus and concomitant CKD who were undergoing coronary/peripheral arterial angiography with
or without percutaneous intervention [9]. Liang et al. also reported, in meta-analysis data including
15 randomized controlled trials, that moderate- or high-dose rosuvastatin treatment could reduce the
incidence of CIN in patients undergoing coronary angiography or PCI [11]. Another meta-analysis by
Yang et al. compared rosuvastatin treatment with no-statin treatment in preventing CIN, and found
that compared to the control group, patients treated with rosuvastatin had a 51% lower risk of CIN
(OR = 0.49, 95% CI = 0.37–0.66, p < 0.001) [13]. However, this meta-analysis showed that rosuvastatin
treatment had no effect in terms of preventing CIN in patients with CKD undergoing elective coronary
procedure (OR = 0.81, 95% CI = 0.41–1.61, p = 0.55). These conflicting results might be attributed to the
differences in the definitions of CIN, study design, patient population, statins used, and the dosage
and duration of statin pretreatment in the different studies.
The pleiotropic effects of different statins vary. Whether rosuvastatin is superior to atorvastatin
in the prevention of CIN is not clear. A large prospective, observational study by Liu et al.
compared the effects of rosuvastatin and atorvastatin for the prevention of CIN in patients with
CKD undergoing PCI (273 patients received rosuvastatin 10 mg and 805 patients received atorvastatin
20 mg), and demonstrated that the preventive effect of both statins for the occurrence of CIN was
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similar [17]. In consideration of the complex mechanisms of CIN, rosuvastatin and atorvastatin have
their own characteristics in the prevention of CIN.
Pitavastatin was no less effective than atorvastatin and simvastatin in presumed equipotent
dosages, and was superior to pravastatin, in lowering LDL-C levels [18,19]. Pitavastatin provided
sustained LDL-C-lowering efficacy and was associated with short- and longer-term improvements in
several other lipid parameters [20,21]. Short- and longer-term outcomes in studies on Asian patients
were consistent with these findings [22,23]. Pitavastatin was also generally well tolerated and did not
appear to adversely affect glucose metabolism parameters. Thus, pitavastatin is an effective treatment
option in adults with primary hypercholesterolemia and combined dyslipidemia, including those
at risk of developing type 2 diabetes. However, there are no data evaluating the efficacy and safety
of pitavastatin on the prevention of CIN in patients with CKD undergoing a coronary procedure.
The current study is of value through its double blinded, placebo-controlled design, enrolling two
groups of patients with a relatively homogenous risk profile. Furthermore, to the best of our knowledge,
this is the first study evaluating the role of pitavastatin for the prevention of CIN in patients with
mild-to-moderate CKD undergoing elective coronary procedure. Moreover, in this study, high-dose
pitavastatin was administered after coronary procedure for a relatively long period (4 mg/day for
10 days), compared with previous studies. Our results show that pitavastatin might reduce the risk
of CIN and preserve renal function, even in patients with normal lipid levels. Therefore, the present
study indicated that in addition to hydration, pitavastatin should be administered to all patients with
mild-to-moderate CKD who receive contrast medium.
Our study has a number of limitations. Due to difficulty of enrollment, the number of patients
in our study was relatively small. Therefore, our study does not have statistical power to prove our
hypothesis. Due to the heterogeneity of patients to develop CIN, further large-scale studies are required
to explore the benefits of pitavastatin pretreatment for prevention of CIN according to baseline eGFR.
Although pitavastatin was administered for 10 days in the periprocedural period, which is longer than
the period of administration in previous studies, the duration of statin treatment may be insufficient for
exercising a protective effect against acute renal injury. In addition, the accurate dose of pitavastatin is
another issue, because most previous studies showing the protective effect of statin for the prevention
of CIN used high doses of the most potent statins, such as atorvastatin or rosuvastatin.
5. Conclusions
This study showed a possibility of clinical benefit of pretreatment with high-dose pitavastatin for
prevention of CIN in patients with CKD after a coronary procedure.
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